S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.01 (+0.59%)
F   12.15 (-0.82%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.08 (+0.31%)
DIS   107.68 (-1.61%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.86 (+2.05%)
NASDAQ:SYNH

Syneos Health (SYNH) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$42.97
$42.99
50-Day Range
$42.48
$42.98
52-Week Range
$22.89
$52.23
Volume
7.39 million shs
Average Volume
1.92 million shs
Market Capitalization
$4.46 billion
P/E Ratio
62.29
Dividend Yield
N/A
Price Target
$40.00

Syneos Health MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
6.9% Downside
$40.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.00
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.68 out of 5 stars

Medical Sector

844th out of 932 stocks

Diagnostics & Research Industry

1st out of 1 stocks


SYNH stock logo

About Syneos Health Stock (NASDAQ:SYNH)

Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.


SYNH Stock News Headlines

Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE!
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets…FOR FREE!
Syneos Health Releases 2024 Health Trends
Syneos Health Appoints Colin Shannon To Succeed Michelle Keefe As CEO
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets… FOR FREE!
Income Expert and Author of Get Rich With Dividends Is Giving Away His Top Income Secrets…FOR FREE!
SYNH Syneos Health, Inc.
Syneos Health execs in line for huge payouts with $7B buyout
Syneos Deadline Alert
See More Headlines
Receive SYNH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syneos Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2021
Today
2/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
NASDAQ:SYNH
Employees
28,768
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.00
High Stock Price Target
$43.00
Low Stock Price Target
$37.00
Potential Upside/Downside
-6.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$266.50 million
Pretax Margin
1.53%

Debt

Sales & Book Value

Annual Sales
$5.39 billion
Cash Flow
$6.72 per share
Book Value
$33.96 per share

Miscellaneous

Free Float
103,366,000
Market Cap
$4.46 billion
Optionable
Optionable
Beta
1.58
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives















SYNH Stock Analysis - Frequently Asked Questions

Should I buy or sell Syneos Health stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SYNH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SYNH, but not buy additional shares or sell existing shares.
View SYNH analyst ratings
or view top-rated stocks.

What is Syneos Health's stock price target for 2024?

4 brokerages have issued 1-year price targets for Syneos Health's stock. Their SYNH share price targets range from $37.00 to $43.00. On average, they expect the company's share price to reach $40.00 in the next year. This suggests that the stock has a possible downside of 6.9%.
View analysts price targets for SYNH
or view top-rated stocks among Wall Street analysts.

How were Syneos Health's earnings last quarter?

Syneos Health, Inc. (NASDAQ:SYNH) released its earnings results on Wednesday, November, 3rd. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.05. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.34 billion. Syneos Health had a trailing twelve-month return on equity of 8.63% and a net margin of 1.31%. Syneos Health's revenue for the quarter was up 22.7% on a year-over-year basis. During the same period last year, the firm posted $0.93 EPS.

What is Alistair Macdonald's approval rating as Syneos Health's CEO?

322 employees have rated Syneos Health Chief Executive Officer Alistair Macdonald on Glassdoor.com. Alistair Macdonald has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Block (SQ), Advanced Micro Devices (AMD), Boeing (BA), Alibaba Group (BABA), ICON Public (ICLR), Netflix (NFLX), AbbVie (ABBV) and Intel (INTC).

This page (NASDAQ:SYNH) was last updated on 2/21/2024 by MarketBeat.com Staff